Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Launched by NOVARTIS PHARMACEUTICALS · Dec 5, 2022

Keywords

ClinConnect Summary

The SIRIUS-SLE 1 trial is a research study looking at how well two different ways of using a medication called ianalumab work for people with systemic lupus erythematosus (SLE), a condition where the immune system mistakenly attacks the body. This trial compares the effects of ianalumab versus a placebo (a dummy treatment) when given as injections either once a month or once every three months, in addition to the standard treatments patients are already receiving for their lupus. The goal is to see if ianalumab can help reduce the symptoms of SLE safely and effectively.

To join the study, participants must be at least 12 years old (or 18 in certain regions) and have a confirmed diagnosis of SLE for at least six months. They should also have specific signs of active disease, like elevated antibody levels and certain disease activity scores. Participants can expect to receive regular injections and will be monitored for their health throughout the study. It’s important to know that individuals with certain medical conditions or recent treatments may not be eligible to participate. This trial is currently recruiting participants, and it aims to gather valuable information that could help improve treatment options for people with lupus in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female participants aged 12 years or older at the time of screening, or limited to 18 years or older in European Economic Area countries and other countries where inclusion of participants below 18 years is not allowed.
• • Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to screening.
• • Elevated serum titers at screening of anti-nuclear antibodies ≥ 1:80 as determined by a central laboratory with a SLE-typical fluorescence pattern.
• • Currently receiving CS and/or anti-malarial treatment and/or another disease-modifying antirheumatic drug (DMARD) as specified in the protocol.
• • SLEDAI-2K criteria at screening: SLEDAI-2K score ≥ 6 points, excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome"
• * BILAG-2004 disease activity level at screening of at least 1 of the following:
• • BILAG-2004 level 'A' disease in ≥ 1 organ system, Or
• • BILAG-2004 level 'B' disease in ≥ 2 organ systems
• • Weigh at least 35 kg at screening
• Exclusion Criteria:
• • Prior treatment with ianalumab
• • History of receiving following treatment: I) high dose CS, calcineurin inhibitors, JAK or other kinase inhibitors or other DMARD (except as listed in inclusion criteria) administered within 12 weeks prior to screening. II) cyclophosphamide or biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti-CD40 agents, CTLA4-Fc Ig or B-cell activating factor (BAFF)-targeting agents administered within 24 weeks prior to screening; belimumab administered within 12 weeks prior to screening. III) any B cell-depleting therapies, other than ianalumab administered within 36 weeks prior to randomization or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). IV) Traditional Chinese medicines administered within 30 days prior to randomization.
• • Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection
• • Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
• • Evidence of active tuberculosis infection
• • History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV) test result at screening
• • Any one of the following abnormal laboratory values prior to randomization
• • Platelets \< 25000/mm\^3 (\< 25 x 10\^3/μL)
• • Hemoglobin (Hgb) \< 8.0 g/dL (\< 5 mmol/L), or \< 7.0 g/dL (\< 4.3 mmol/L) if related to participant's SLE such as in active hemolytic anaemia
• • Absolute neutrophil count (ANC) (\< 0.8 x 10\^3/ μL)
• • Severe organ dysfunction or life-threatening disease at screening
• • Presence of severe lupus kidney disease as defined by proteinuria above 2 g/day or equivalent using spot urine protein creatinine ratio, or serum creatinine greater than 2.0 mg/dL (176.84 µmol/L), or requiring immune-suppressive induction or maintenance treatment at screening
• • Receipt of live/attenuated vaccine within a 4-week period before first dosing
• • Any uncontrolled, co-existing serious disease, which in the opinion of the investigator will place the participant at risk for participation or interfere with evaluation for SLE-related symptoms
• • Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or chronic treatment with systemic CS
• • History of malignancy of any organ system other than localized basal cell carcinoma of the skin or in situ cervical cancer
• • Pregnant or nursing (lactating) women.
• • Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while on study treatment and for 6 months after stopping of investigational drug.
• • Any surgical, medical, psychiatric or additional physical condition that may jeopardize participation in this study